Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 224-230

  Wilson, George S ^a   Tian, Aiping ^b   Hebbard, Lionel ^a   Duan, Wei ^c   George, Jacob ^a   Li, Xun ^b   Qiao, Liang ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LANZHOU UNIVERSITY   (China)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Hepatocellular carcinoma; JAK signalling; Ruxolitinib

Indexed keywords

INC 424; JANUS KINASE; RUXOLITINIB; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PYRAZOLE DERIVATIVE; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; DOSE RESPONSE; DRUG EFFECTS; HUMAN; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASES; LIVER NEOPLASMS; PYRAZOLES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84887132275     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.009     Document Type: Article

References (38)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Stat. 2002.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. CA Cancer J. Clin. 2005, 55:74-108.
3. Espey D.K., Wu X.C., Swan J., Wiggins C., Jim M.A., Ward E., Wingo P.A., Howe H.L., Ries L.A.G., Miller B.A., Jemal A., Ahmed F., Cobb N., Kaur J.S., Edwards B.K. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska natives. Cancer 2007, 110:2119-2152.
4. Yuen M.F., Hou J.L., Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009, 24:346-353.
5. Lai S.Y., Childs E.E., Xi S., Coppelli F.M., Gooding W.E., Wells A., Ferris R.L., Grandis J.R. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005, 24:4442-4449.
6. Ward A.C., Touw I., Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000, 95:19-29.
7. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.-S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
8. Lee Y.H., Yun Y. HBx Protein of Hepatitis B Virus Activates Jak1-STAT Signaling. J. Biol. Chem. 1998, 273:25510-25515.
9. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
10. Yoshikawa H., Matsubara K., Qian G.-S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28:29-35.
11. Duan Z., Bradner J., Greenberg E., Mazitschek R., Foster R., Mahoney J., Seiden M.V. 8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7 dicarboxylic Acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol. Pharmacol. 2007, 72:1137-1145.
12. Fulda S., Wick W., Weller M., Debatin K.-M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
13. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
14. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell 2009, 16:487-497.
15. Scuto A., Krejci P., Popplewell L., Wu J., Wang Y., Kujawski M., Kowolik C., Xin H., Chen L., Wang Y., Kretzner L., Yu H., Wilcox W.R., Yen Y., Forman S., Jove R. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011, 25:538-550.
16. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., Estrov Z., Fridman J.S., Bradley E.C., Erickson-Viitanen S., Vaddi K., Levy R., Tefferi A. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N. Engl. J. Med. 2010, 363:1117-1127.
17. Wang Y., Ma X., Yan S., Shen S., Zhu H., Gu Y., Wang H., Qin G., Yu Q. 17-Hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3signaling by covalently cross linking janus kinases and induces apoptosis of human cancer Cells. Cancer Res. 2009, 69:7302-7310.
18. Zhou J., Ong C.N., Hur G.M., Shen H.M. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem. Pharmacol. 2010, 79:1242-1250.
19. Quintas-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., Caulder E., Wen X., Li Y., Waeltz P., Rupar M., Burn T., Lo Y., Kelley J., Covington M., Shepard S., Rodgers J.D., Haley P., Kantarjian H., Fridman J.S., Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
20. Corvinus F.M., Orth C., Moriggl R., Tsareva S.A., Wagner S., Pfitzner E.B., Baus D., Kaufmann R., Huber L.A., Zatloukal K., Beug H., Ohlschlager P., Schutz A., Halbhuber K.-J., Friedrich K. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
21. Ferrajoli A., Faderl S., Ravandi F., Estrov Z. The JAK-STAT Pathway: a therapeutic target in hematological malignancies. Curr. Cancer Drug Targets 2006, 6:671-679.
22. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
23. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679.
24. Sriuranpong V., Park J.I., Amomphimoltham P., Patel V., Nelkin B.D., Gutkind J.S. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the Interleukin 6/gp130 cytokine system. Cancer Res. 2003, 63:2948-2956.
25. Thoennisen N.H., Iwanski G.B., Doan N.B., Okamoto R., Lin P., Abbassi S., Song J.H., Yin D., Toh M., Xie W.D., Said J.W., Koeffler H.P. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009, 69:5876-5884.
26. To K.F., Chan M.W.Y., Leung W.K., Ng E.K.W., Yu J., Bai A.H.C., Lo A.W.I., Chu S.H., Tong J.H.M., Lo K.W., Sung J.J.Y., Chan F.K.L. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br. J. Cancer 2004, 91:1335-1341.
27. He G., Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
28. Park E.J., Lee J.H., Yu G.-Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
29. Inamura K., Matsuzaki Y., Uematsu N., Honda A., Tanaka N., Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim. Biophys. Acta 2005, 1745:401-410.
30. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
31. Seavey M.M., Dobrzanski P. The many faces of Janus kinase. Biochem. Pharmacol. 2012, 83:1136-1145.
32. Ostojic A., Vrhovac R., Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011, 7:1035-1043.
33. Looyenga B.D., Hutchings D., Cherni I., Kingsley C., Weiss G.J., Mackeigan J.P. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS ONE 2012, 7:e30820.
34. Jee S.H., Chu C.Y., Chiu H.C., Huang Y.L., Tsai W.L., Liao Y.H., Kuo M.L. Interleukin-6 induced basic fibroblast growth factor dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J. Invest. Dermatol. 2004, 2004:1169-1175.
35. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., Peng Z., Huang S., Xiong H.Q., Abbruzzese J.L., Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.
36. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
37. Shi J.G., Chen X., Emm T., Scherle P.A., McGee R.F., Lo Y., Landman R.R., McKeever E.G., Punwani N.G., Williams W.V., Yeleswaram S. The Effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered Ruxolitinib (INCB018424 Phosphate) in healthy volunteers. J. Clin. Pharmacol. 2012, 52:809-818.
38. Poelstra K., Prakash J., Beljaars L. Drug targeting to the diseased liver. J. Controlled Release 2012, 161:188-197.